Impel Pharmaceuticals Inc.

IMPLNASDAQHealthcare

$0.04

$-0.02(-27.27%)

Market Cap$956000

P/E Ratio—

52W High$4.2

52W Low$0.0212

Avg Volume1.0M

Open$0.05

Beta1.17

Overview

Impel Pharmaceuticals Inc. (IMPL) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

IMPL · free cash flow · updated Jun 9, 2026

Core FCF metrics

IMPL · FCF · TTM · margin & CAGR

Free cash flow was −$95.0M for FY2022 (fiscal year ending 2022-12-31), down 42.3% year-over-year The FCF margin was -751.0%.

FY2022 Free Cash Flow−$95.0M▼ -42.3% YoY

Trailing 12M (TTM)−$82.0Mtrailing 4 quarters sum

FCF Margin-751.0%−$95.0M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

IMPL · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2022Latest−$93.6M(1M)−$95.0M▼ 42.3%-751.0%

FY2021−$66.4M(0M)−$66.8M▼ 63.0%—

FY2020−$39.2M(2M)−$41.0M▼ 7.8%—

FY2019−$36.5M(2M)−$38.0M——

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

IMPL · P/FCF · FCF yield · FCF per share

Impel Pharmaceuticals Inc. (IMPL) reported negative free cash flow of −$0.10B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2022 · 2022-12-31

Cash flow statement summary

IMPL · cash flow statement · operating / investing / financing

For FY2022, Impel Pharmaceuticals Inc. generated −$93.6M in operating cash flow and spent 1M in capital expenditures, yielding −$95.0M in free cash flow.

Operating Activities

−$93.6M

Cash from core business operations

2022-12-31

Investing Activities

−$1.4M

CapEx, acquisitions & investments

2022-12-31

Financing Activities

+$67.5M

Buybacks, dividends & debt

2022-12-31

FCF FormulaOperating CF (−$93.6M) − |CapEx| (1M) = FCF (−$95.0M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

IMPL vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Impel Pharmaceuticals Inc.YOU

IMPL

−$95.0M-42.3%-751.0%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Impel Pharmaceuticals Inc. (IMPL) reported free cash flow of −$95.0M for FY2022 (fiscal year ending 2022-12-31), down 42.3% year-over-year. The FCF margin was -751.0%.

Impel Pharmaceuticals Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 4 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

IMPL free cash flow · 8 questions

Impel Pharmaceuticals Inc. free cash flow was −$95.0M for FY2022, down 42.3% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$82.0M.

IMPL free cash flowIMPL FCFIMPL FCF 2022IMPL free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Impel Pharmaceuticals Inc. · Impel Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026